BTOG 2019 | Securing SABR: improving access in the UK

With recent data showing that stereotactic ablative body radiotherapy (SABR) improves outcomes in early stage and oligometastatic lung cancer, improving access to this treatment is a priority, as discussed here by Iain Phillips, MBBS, BSc, MSc, MRCP, FRCR, of NHS Lothian, Edinburgh, UK. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.